Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5386_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
16 Мб
Скачать
☆
184
Nano Physical Pharmaceutics of Nanogel Delivery System
hand, an increase in the concentration of salt leads to a decrease
          
nanogel, reducing the absorption of the internal solute with the opposite charge. In addition, the ions and the change in the local
         
the charged-polymer network, resulting in internal inhomogeneity in polymer density [47].
Arturo et al. explored the charge distribution of charged nanomaterials in electrolyte water suspensions through Monte Carlo simulation and Ornstein–Zernike integral equation theory, and considered the size of ions, the swelling or shrinkage state of the gel, the valence state of the counterions, the type of charge carried by the gel, as well as the interaction between electrostatic
           
contraction, electrostatic repulsion between charged groups will lead to an uneven distribution of polymer and form a low­density pore structure surrounded by dense corona. The excluded volume repulsion strongly inhibits the penetration of ions in the
      
concentration at the dense structure. In general, the properties
        
the valence of counter ions and the charge of nanogels. On the one hand, with the increase of the valence of counter ions, the charged monomer enters into the inner and outer layers near the coronal structure, forming a shrunken-down nanogel. On the other hand, increasing the charge of particles can promote the
   
radius of nanomaterials [48].
5.4.5 Drug Release Behavior of Stimulus-Responsive
Nanogels
Nanogels can integrate drugs, proteins and DNA through physical and chemical methods, and also have adjustable chemical framework, swelling rate, mechanical strength and other properties. Nanogels are also known as smart materials because they can respond to external stimuli (such as pH, temperature, light, etc.) by changing their volume, hydrophilicity, refractive index, etc. [49].
        
NPP of Nanogels in Drug Delivery
185

a feedback mechanism. The drug-loaded nanogels are in a contracted state under normal conditions. After receiving disease information, they can respond and expand the volume to promote
          
the nanogel shrinks and prevents the continued release of the drug, so as to achieve the intelligent and controlled release of
       
pH- and glucose-responsive nanomaterials have been developed for applications in drug transport, biological imaging, etc. [50].
5.4.5.1 Temperature-responsive nanogels
Temperature-responsive nanogels are one of the most frequently studied environmentally sensitive systems in drug delivery. The structure of this type of nanogel contains a certain ratio of hydrophilic and hydrophobic groups. Changes in temperature
        
promoting changes in the network structure and volume of the hydrogels. In the hydrogel solvent system, there are generally two kinds of temperature-responsive phase transitions, that is, lower critical solution temperature (LCST) and upper critical solution temperature (UCST). Between them, the LCST-type polymer gel shrinks at a temperature above the critical value, while the UCST-type polymer gel shrinks at a temperature below the critical point. The former is widely used in the temperature­driven drug release strategy.
Poly(N-isopropylacrylamide) is currently the most widely used polymer with temperature stimulus responsiveness because its LCST is close to human physiological temperature. While poly (N,N-diethylacrylamide) has a slightly lower LCST at 25 °C–32 °C. It can also be used for drug delivery. However, copolymers of acrylamide (AAM) and N-isopropylacrylamide (NIPAAm) are used to prepare temperature-responsive photothermally adjustable drug delivery systems. The LCST of copolymers can be adjusted by changing the concentration of AAM. For example, increasing the ratio of AAM/NIPAAm can increase the LCST from 32 °C to 60 °C. The gel is used to encapsulate gold nano sheet, which can cause local temperature rise by absorbing near-infrared radiation (NIR),
186
Nano Physical Pharmaceutics of Nanogel Delivery System
leading to rapid contraction of the gel and the release of the encapsulated drug [51].
5.4.5.2 pH-responsive nanogels
The swelling properties of pH-responsive nanomaterials mainly originate from the ionizable acidic or alkaline groups on the
               
the apparent dissociation constant (Ka      the corresponding monobasic or monobasic Ka. The existence of ionizable groups causes electrostatic repulsion between polymer chains, and the swelling degree of the corresponding hydrogel is much higher than that of the hydrogel formed by non-electrolyte polymers. Therefore, the degree of gel swelling can be controlled
       
the pH, ionic strength, and type of counter ion of the medium. Moreover, the swelling degree of hydrogels can be regulated by co-polymerization of neutral monomers (e.g., methyl methacrylate),
       
At present, polyethylene glycol grafted anionic polymethacrylic acid-based nanogels have been developed for oral drug delivery. When the environmental pH is around 2, the pore size of the gel is smaller due to the formation of hydrogen bonds between the carboxylic acid groups and the oxygen atoms on the polymethacrylic and polyethylene glycol respectively. When the pH increases to 7, methacrylic acid is deprotonated, attracting water molecules to enter and causing the hydrogel to swell. This phenomenon is adapted to the conditions of the digestive system, that is, it can protect the drugs in the stomach (low pH environment), while
          
intestine [52].
5.4.5.3 Glucose-responsive nanogels
Glucose-sensitive nanogels can swell or collapse in response to changes in glucose concentration, and mainly used in the
       
NPP of Nanogels in Drug Delivery
187
sensitive materials are mainly divided into three types: glucose oxidase (GOD), concanavalin (Con A) and phenylboric acid (PBA). The GOD system is inherently pH sensitive. It generates gluconic acid and hydrogen peroxide through the reaction of glucose oxidase and glucose, which leads to a decrease in local pH, causes
                     
agglutinin with four glucose-binding sites. Agglutinins interact with various cells by reacting with glycoproteins and glycolipids on the cell surface. Glucose-sensitive gel prepared by cross-linking with concanavin (Con A) and carboxymethyl dextran, when free glucose competes with the oligosaccharide site of Con A in the external environment, the gel structure is loose and insulin is released [54].
Although glucose-responsive nanogels have excellent performance as an insulin delivery system, they still need improvement in various aspects before clinical application. Their application constraints include slow response to changes in glucose concentration in the environment, and reducing the size of nanogels may be a way to shorten the response time. Besides, they lack a high repeatability and rapid response to the changing glucose concentration, and the ingredients used may induce adverse immune reactions [55].
5.4.5.4 Photoresponsive nanogels
Photoresponsive nanogel is a kind of gel that can change in volume under the condition of light radiation, which is generally divided
     
groups, such as triphenylmethane and azobenzene, etc., which will undergo photodissociation or isomerization under light irradiation, resulting in swelling of the gel. The other type belongs to hybrid systems, which are nanoparticles with metal and temperature-sensitive groups in the nanogel structure [56]. The principle is that metals such as gold and silver can convert light into heat, so the temperature in the system increases, and temperature-sensitive groups make the nanogel responsive [57]. A light and temperature-sensitive nanogel is shown in Fig. 5.4.
188
Nano Physical Pharmaceutics of Nanogel Delivery System
5.4.5.5 Other stimulation-responsive nanogels
        
stimulus-responsive nanogels have been developed. Magnetic responsive nanogel is a kind of magnetic-sensitive nanogel system containing magnetic materials such as Fe3O4, Fe2O3. It has good magnetic responsive drug release characteristics and has great application prospects in the diagnosis and treatment of tumors [58, 59]. Nanogels with double or multiple responses have also gradually emerged, such as the magnetic/temperature dual response system [60], temperature/pH dual response system [61], pH/magnetic dual response system [59], and temperature/ pH/magnetic multiple-response system [62]. Double or multiple­response nanogels combine the advantages of each response monomer and have more potential, which is worthy of further investigation.
5.4.6 Biological Applications of Nanogel Delivery
Systems
With the development of nanotechnology, biomedicine and smart materials, nanogels have shown attractive application prospects due to their excellent drug-loading properties and drug release ability, so they have attracted great attention.
5.4.6.1 Delivery of small-molecule therapeutic drugs
The application of nanogels for drug delivery is an important direction of current research, which mainly has the following three advantages: targeted therapy, controlled release and long circulation. Nanogels are prepared from amphipathic block copolymers, PEG-b-polymethacrylic acid (PEG-b-PMA) can be synthesized via ionic complexation and cross-linking reaction with a swollen PMA cross-linking network as the core and PEG chain as the shell. This synthesis method can adjust the macro characteristics (e.g., size and swelling degree) of nanogels, by changing the cross-links number or chemical structure [63]. Compared with other nanocarriers, this nanogel shows very low
   
Moreover, nanogels with such core and shell can load a large
NPP of Nanogels in Drug Delivery
189
amount of (50%) doxorubicin (DOX) through the electrostatic adsorption of the carboxyl group of the core, which can not only remain stable for a long time but also promote the release of DOX after being protonated in an acidic environment. Meanwhile, it shows good cytotoxicity to tumor cells. The author further used the nanogel to contain the hydrophilic chemotherapeutic drug cisplatin, which not only achieved pH-responsive release but also
        
degree of cross-linking of the inner core. The released platinum drugs remained active and could form platinum adducts with the DNA in the nucleus of the tumor cell. The experimental results of the mouse model of ovarian cancer indicated that the nanogel
       
increasing the drug concentration at the tumor delivery site and reduce the nephrotoxicity of platinum drugs to improve the safety
     
inhibited by modifying the drug-loaded nanogels with targeted ligands (e.g., folic acid, LHRH peptide).
5.4.6.2 Delivery of oligonucleotides
Therapeutic oligonucleotides (e.g., small interfering RNA (siRNAs) and antisense oligodeoxynucleotides (ODNs)), can diagnose and treat tumors, neurodegenerative diseases, lethal virus infections,
       
mRNA sequences. Although some oligonucleotide-based treatment
         
deliver them to target cells is still an urgent concern. Because oligonucleotides are hydrophilic molecules with a negative charge, they cannot penetrate the cell membrane and can be degraded by a variety of endogenous nucleases to stimulate the inherent immune response. Therefore, oligonucleotides need a delivery system to deliver them to the target site without causing side
        
composed of polymer polyelectrolytes or copolymers of ionic monomers, giving the gel surface a certain charge. It is able to achieve targeted delivery by adsorbing DNA fragments, bases and other substances, wrapping or forming complexes, and
190
Nano Physical Pharmaceutics of Nanogel Delivery System
         
same mechanism of action as that of drug delivery systems.
        
deliver nucleic acids such plasmid DNA, siRNA molecules. However, endocytosis or binding of oligonucleotides is not enough to keep
                                   
Figure 5.5 shows the general process of DNA-nanogel polyplex formation and release as conducted in our group. It is easily seen that the polyplex formed by a positively charged chain like PEI is not stable because the size and polydispersity (PDI) are large due to the interparticle aggregation. On the other hand, in the polyplex formed by the positively charged nanogel, the negative pDNA is absorbed and trapped in the nanogel resulting in a stable and uniform polyplex.
Figure 5.5 The mechanism of DNA complex and polyplex stability as interacted with caonic nanogel (such as PNIPAM-PEI nanogel) and cationic
polymers (such as PEI).

Summary and Perspective

191
5.4.6.3 Delivery of therapeutic proteins
Nanogels can be used to encapsulate biological macromolecules, such as proteins and peptides, to prevent them from being
    
amylopectin (CHP) gels can form a variety of complex protein complexes through hydrophobic interaction. The complexation
       
proteins and protect them from enzyme degradation. The amount of complexation is related to the hydrophobicity and of molecular weight proteins [64]. However, the protein complexes are unstable under high protein concentration. To improve the long-term stability of the complexes, nanogels with strawberry-like structures
        
nanogels (40 nm–120 nm). The nanogels had a high encapsulation rate of interleukin-12 (IL-12), and IL-12 level in plasma remained stable after subcutaneous injection for 72 h. Shi et al. synthesized acid-resistant nanogels of N-vinylformamide through inverse emulsion polymerization, and the drug loading of lysozyme was up to 60%. About 95% of lysozyme was released at pH 5.8 after 3 h; at pH 7.4; at the same time, only 15% of lysozyme was released, while the released lysozyme retained about 50% of its
         
consistency, and stability after loading are still problems to be considered.
5.5 Summary and Perspective
With the continuous improvement of biomedical technology, the
  
and treatment systems is also increasing. Nanogels show
      
water content and good biocompatibility. With the continuous improvement of nanogel design theory, it is possible to design more functional carrier systems according to the demand by
               
192
Nano Physical Pharmaceutics of Nanogel Delivery System
and so on. However, how to improve the biocompatibility and biodegradability of nanogels is still a huge challenge. With the continuous improvement of synthesis and preparation technologies, it is expected that extensive clinical application of nanogels may be achieved, and new therapies for diseases may be developed.
References
1. 17Li W, Wang WF, Li RQ, Yao SD, , , 624–630.
2. Cheng
4.
8. Murthy
9. Goh SL, Murthy N, Xu M,
13.
15. Bronich TK, Keifer
CC, Liang MC, Liao ZS, Huang
, 1600370.
Akiyoshi K, Sunamoto J,
Daoud-Mahammed S, Couvreur 185–191.
Fernández A, Vilanova M, Gama 638–646.
100
, 4995–5000.

Oh JK,
2006
Pharmaceut
Kohli E, Han HY, Zeman ,
, 19–27.
121
Vinogradov SV, Kohli E, Zeman AD,
Soc
2005, 127
Release 2007, J 121
Kobayashi S, Shichibe
J Control Release
N, Xu M, Schuck S, Fréchet JMJ,
Tang
C, Gao H, Tsarevsky NV, Matyjaszewski K,
, 128
, 5578–5584.
C, Robinson
2002, 245
DN,
, 83–91.
PA, Shlyakhtenko
, 8236–8237.
, 10–18.
Nucl Tech
1998, 54
Biopolymers
Langmuir
A, Lima CF,
Fréchet JMJ, , ,
Colombo
Adv Drug Deliver Rev
AD, Vinogradov SV,
2002
025
JJ, Lee
DJ,
Macromol Biosci
S,
Mix D, Baudys M, Kim SW,
, 313–320.
P, Gref R, , ,
FM,
P, Giordano F, Peppas
Pharm Res
Int , J Pharm
2006
83
2006 22
Olmedo
Toxicol In Vitro
P Natl Acad Sci
Bioconjug Chem 2004 15
J Control Release 2007
2006 23
LS, Kabanov
Cho MJ, DeSimone JM, Control
2007 332
, 148–158.
MP,
J Am Chem
2002
54, 13–36.
, , 920–930.
AV,
J Am Chem
2016,
González-
, 29
USA 2003,
Soc
NA,
Int J
,
References
193
17. Carothers WH, Trans Faraday Soc 1936, 32, 39.
18. Flory PJ, Principles of Polymer Chemistry, Cornell University Press, Cornell, 1953.
19. Tang AQ, Statistical Theory of Polymeric Reactions, Science Press, Beijing, 1985.
20. Tang AQ, Jaing YS, Wang MJ, Chinese J Polym Sci 1963, 5, 35.
21. Tang AQ, Shen JC, Special Issue of Polymer Academic Conference of Chinese Academy of Sciences, Science Press, Beijing, 1961, p. 163.
22. Tang AQ, Science China 1963, 11, 605.
23. Li W, Wei H, Li H, Gao J, Feng S-S, Guo Y, Nanomedicine 2014, 9, 2587–2605.
24. Donnelly C, Tian Y, Potter C, Jones DS, Andrews GP, Pharm Res 2015, 32, 167–179.
25. Soni G, Yadav KS, Saudi Pharm J 2016, 24, 133–139.
26. Huang N, Guan Y, Zhu XX, Zhang Y, Chemphyschem 2014, 15, 1785–1792.
27. Guzman-Sepulveda JR, Deng J, Fang JY, Dogariu A, Soft Matter 2016, 12, 5986–5994.
28. Kabanov AV, Vinogradov SV, Angew Chem Int Ed Engl 2009, 48, 5418–5429.
29. Brannon-Peppa L, Peppas NA, Biomaterials 1990, 11, 635–644.
30. Bontha S, Kabanov AV, Bronich TK, J Control Release 2006, 114, 163–174.
31. Su DS, Wang SL, Physical Pharmacy, Chemical Industry Press, Beijing,
2004.
32. Belmaker RH, Hermoni M, Lerer B, Ebstein RP, Belmaker RH, J Pharm Pharmacol 1980, 32, 510–511.
33. Kumar V, Prud’homme RK, J Pharm Sci 2008, 97, 4904–4914.
34. Li Y, Maciel D, Rodrigues J, Shi X, Tomas H, Chem Rev 2015, 115, 8564–8608.
35. Li W, Guo Q, Zhao H, Zhang L, Li J, Gao J, Qian W, Li B, Chen H, Wang H, Dai J, Guo Y, Nanomedicine 2012, 7, 383–392.
36. Bütün V, Wang XS, de Paz Báñez MV, Robinson KL, Billingham NC, Armes SP, Tuzar Z, Macromolecules 2000, 33, 1–3.
37. Mackiewicz M, Romanski J, Drozd E, Gruber-Bzura B, Fiedor P, Stojek Z, Karbarz M, Int J Pharm 2017, 523, 336–342.